|Bid||7.00 x 0|
|Ask||7.50 x 0|
|Day's Range||7.00 - 7.30|
|52 Week Range||6.70 - 12.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LONDON, UK / ACCESSWIRE / April 23, 2018 / With the refocusing of the business and the new CEO's strategic review now implemented, e-Therapeutics (LSE: ETX) finds itself with the NDD platform and at least ...
LONDON, UK / ACCESSWIRE / January 5. 2018 / e-Therapeutics' (LSE: ETX) Network-Driven Drug Discovery (NDD) platform has begun to deliver encouraging data that should support out-licensing of its immuno-oncology ...
e-Therapeutics plc : Upon the completion of Ray Barlow’s first three months as CEO of e-Therapeutics, the Company outlines below the conclusion of the strategic review for its investors and other stakeholders.